NEW! Drugs for Rare Diseases (DRD) Sub-Report

Add-On To Canadian Reimbursement and Forecasting Timelines (CRaFT)
April 2022 Edition

Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Drugs for Rare Diseases (DRD) Sub-Report offers credible, relevant insights related to DRD files to support a company’s reimbursement forecasting needs.

WHY DO YOU NEED THIS SUB-REPORT?

The CRaFT DRD Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the DRD public market reimbursement process – from HTA submission to provincial funding.

WHAT DOES THE REPORT INCLUDE?

This CRaFT DRD Sub-Report includes 30+ page of insights on DRD drugs reviewed by CADTH from 2017-2021 related to:

  • CADTH review volume & timeline
  • pCPA volume for initiated, completed, closed, and not-negotiated files
  • pCPA under-consideration and under-negotiation timeline
  • Funding volume & timeline for each jurisdiction
  • Timeline Comparison: DRD and Other Types of Files
  • Market access timeline forecasting (from HTA submission to first funding)

For further information on the content and pricing of CRaFT and the Drugs for Rare Diseases (DRD) Sub-report, please complete your contact information on our main CRaFT Report page.

← Back to Main CRaFT Report
Canadian Reimbursement and Forecasting Timelines (CRaFT) - Drugs for Rare Diseases Sub-Report, June 2021 Update